methionine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3347 63-68-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methionine
  • L-methionine
  • S-methionine
A sulfur-containing essential L-amino acid that is important in many body functions.
  • Molecular weight: 149.21
  • Formula: C5H11NO2S
  • CLOGP: -1.73
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 63.32
  • ALOGS: -0.80
  • ROTB: 4

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 50 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal growth restriction 76.24 36.49 15 281 7538 63481188
Infantile apnoea 51.44 36.49 8 288 1025 63487701
Selective eating disorder 45.87 36.49 8 288 2064 63486662
Cerebral haemorrhage 41.52 36.49 12 284 30717 63458009

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrolyte imbalance 48.61 38.15 15 524 14397 34941995
Paraplegia 38.83 38.15 9 530 2902 34953490
General physical health deterioration 38.34 38.15 24 515 128245 34828147

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrolyte imbalance 45.33 36.22 15 699 30866 79712808
Paraplegia 38.74 36.22 9 705 5044 79738630
Gaze palsy 37.63 36.22 8 706 2997 79740677
Quadriplegia 36.74 36.22 8 706 3352 79740322

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AB26 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Antidotes
ATC V09IX13 VARIOUS
DIAGNOSTIC RADIOPHARMACEUTICALS
TUMOUR DETECTION
Other diagnostic radiopharmaceuticals for tumour detection
CHEBI has role CHEBI:27027 trace elements
CHEBI has role CHEBI:50733 Dietary Supplement
CHEBI has role CHEBI:74529 antidotes to acetaminophen poisoning
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite
CHEBI has role CHEBI:75772 S. cerevisiae metabolites
CHEBI has role CHEBI:76924 plant metabolites
CHEBI has role CHEBI:76971 Escherichia coli metabolites
CHEBI has role CHEBI:83056 Daphnia magna metabolites
CHEBI has role CHEBI:84735 algal metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Classical phenylketonuria contraindication 7573000
Poisoning by digitalis glycoside contraindication 12876009
Sarcoidosis contraindication 31541009 DOID:11335
Hypertensive disorder contraindication 38341003 DOID:10763
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Hyperlipidemia contraindication 55822004 DOID:1168
Heart disease contraindication 56265001 DOID:114
Hypercalcemia contraindication 66931009 DOID:12678
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.37 acidic
pKa2 9.44 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
S-ribosylhomocysteine lyase Unclassified Ki 4.21 CHEMBL

External reference:

IDSource
4018672 VUID
N0000146983 NUI
D00019 KEGG_DRUG
4018672 VANDF
4018991 VANDF
C0025646 UMLSCUI
CHEBI:16811 CHEBI
MET PDB_CHEM_ID
CHEMBL274119 ChEMBL_ID
CHEMBL42336 ChEMBL_ID
DB00134 DRUGBANK_ID
D008715 MESH_DESCRIPTOR_UI
6137 PUBCHEM_CID
452 INN_ID
4814 IUPHAR_LIGAND_ID
AE28F7PNPL UNII
6837 RXNORM
5074 MMSL
6044 MMSL
NOCODE MMSL
d00489 MMSL
002048 NDDF
002867 NDDF
108956002 SNOMEDCT_US
312184007 SNOMEDCT_US
70288006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ProcalAmine HUMAN PRESCRIPTION DRUG LABEL 22 0264-1915 INJECTION 0.16 g INTRAVENOUS NDA 24 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.34 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.34 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.34 g INTRAVENOUS NDA 23 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3200 SOLUTION 749 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3205 SOLUTION 749 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 749 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 749 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 749 mg INTRAVENOUS ANDA 20 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9010 INJECTION, SOLUTION 0.53 g INTRAVENOUS NDA 24 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9011 INJECTION, SOLUTION 0.53 g INTRAVENOUS NDA 24 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9341 SOLUTION 0.34 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9361 SOLUTION 0.20 g INTRAVENOUS NDA 23 sections
HepatAmine HUMAN PRESCRIPTION DRUG LABEL 16 0264-9371 INJECTION, SOLUTION 0.10 g INTRAVENOUS NDA 23 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 320 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 320 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 320 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 320 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 320 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 320 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 320 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 320 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 200 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 200 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 320 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 320 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 320 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 320 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 320 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 320 mg INTRAVENOUS NDA 20 sections